This inventor holds 3 USPTO granted patents and 2 published patent applications. Top assignee: Daiichi Sankyo Company, Limited. Active years: 2020-2024.
Company Filing History:
Years Active: 2020-2024
Title: Ryuta Mukasa: Innovator in Immunotherapy
Introduction
Ryuta Mukasa is a prominent inventor based in Taito-ku, Japan. He has made significant contributions to the field of immunotherapy, particularly in the development of methods for treating autoimmune diseases. With a total of 3 patents to his name, Mukasa is recognized for his innovative approaches to enhancing T cell regulation.
Latest Patents
Mukasa's latest patents include a composition for depleting cytotoxic T cells using an anti-LAG-3 antibody composition. This composition is designed to effectively reduce the number of LAG-3 positive cells in vivo while maintaining in vitro ADCC activity. Another notable patent involves methods for treating autoimmune diseases, which utilize a monoclonal antibody that binds to domain 3 of human LAG-3. This method not only reduces LAG-3 positive cells but also suppresses experimental autoimmune encephalomyelitis.
Career Highlights
Ryuta Mukasa is currently employed at Daiichi Sankyo Company, Limited, where he continues to advance his research in immunotherapy. His work has garnered attention for its potential to improve treatment outcomes for patients with autoimmune conditions.
Collaborations
Mukasa collaborates with esteemed colleagues, including Kensuke Nakamura and Sumie Muramatsu, to further enhance the impact of his research. Their combined expertise contributes to the innovative solutions being developed in the field.
Conclusion
Ryuta Mukasa's contributions to immunotherapy through his patents and collaborative efforts highlight his role as a key innovator in the medical field. His work promises to pave the way for new treatments that could significantly benefit patients suffering from autoimmune diseases.